Anti-Hu CD79a PE

Anti-Hu CD79a PE
Regulatory status
RUO
Antigen
CD79a
Clone
HM47
Format
PE
Reactivity
Dog, Chicken, Rabbit, Guinea pig, Horse, Cow, Mouse, Rat, Pig, Non-human primates, Human
Application
FC (QC tested)
Excitation laser
blue (488 nm)
Variant
100 tests
1P-731-T100
In stock

25 tests
1P-731-T025
In stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
Images
References
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody HM47 reacts with intracellular domain of CD79a (Ig alpha), a 40-45 kDa subunit of B cell antigen-specific receptor (BCR) and its early developmental forms.
Application
FC (QC tested)
Application details
Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Reactivity
Dog, Chicken, Rabbit, Guinea pig, Horse, Cow, Mouse, Rat, Pig, Non-human primates, Human
Immunogen
Synthetic peptide corresponding to C terminal amino acids 208-222 of human CD79a
Other names
BCR alpha, Ig-alpha, MB-1, IGA
Preparation
The purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide
Storage and handling
Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.
1P-731 FC
Flow cytometry analysis (intracellular staining) of CD79a in human peripheral blood with anti-CD79a (HM47) PE.

General references:

Fuentes-Pananá EM, Bannish G, Karnell FG, Treml JF, Monroe JG: Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation. J Immunol. 2006 Dec 1;177(11):7913-22.
PubMed
Fuentes-Pananá EM, Bannish G, van der Voort D, King LB, Monroe JG: Ig alpha/Ig beta complexes generate signals for B cell development independent of selective plasma membrane compartmentalization. J Immunol. 2005 Feb 1;174(3):1245-52.
PubMed
Fuentes-Pananá EM, Bannish G, Shah N, Monroe JG: Basal Igalpha/Igbeta signals trigger the coordinated initiation of pre-B cell antigen receptor-dependent processes. J Immunol. 2004 Jul 15;173(2):1000-11.
PubMed
Pike KA, Iacampo S, Friedmann JE, Ratcliffe MJ: The cytoplasmic domain of Ig alpha is necessary and sufficient to support efficient early B cell development. J Immunol. 2004 Feb 15;172(4):2210-8.
PubMed
Bannish G, Fuentes-Pananá EM, Cambier JC, Pear WS, Monroe JG: Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J Exp Med. 2001 Dec 3;194(11):1583-96.
PubMed

Product specific references:

Bhargava P, Kallakury BV, Ross JS, Azumi N, Bagg A: CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner. Am J Clin Pathol. 2007 Aug;128(2):306-13.
PubMed
Mason DY, Cordell JL, Tse AG, van Dongen JJ, van Noesel CJ, Micklem K, Pulford KA, Valensi F, Comans-Bitter WM, Borst J, et al.: The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. J Immunol. 1991 Dec 1;147(11):2474-82.
PubMed
Rassenti LZ, Kipps TJ: Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95(8):2725-7.
PubMed
Fernandez NJ, West KH, Jackson ML, Kidney BA: Immunohistochemical and histochemical stains for differentiating canine cutaneous round cell tumors. Vet Pathol. 2005 Jul;42(4):437-45.
PubMed
Torlakovic E, Torlakovic G: B-cell markers in lymphocyte predominance Hodgkin disease. Arch Pathol Lab Med. 2002 Jul;126(7):862-3.
PubMed
Zhao XF, Hassan A, Perry A, Ning Y, Stass SA, Dehner LP: C-MYC rearrangements are frequent in aggressive mature B-Cell lymphoma with atypical morphology. Int J Clin Exp Pathol. 2008 Jan 1;1(1):65-74.
PubMed
Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, Melkus MW, Cravens PD, Martin Mdel P, Netto G, Garcia JV: Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J Virol. 2004 Dec;78(24):13891-900.
PubMed
Variant
100 tests
1P-731-T100
In stock

25 tests
1P-731-T025
In stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock